Clinical Trial Update: A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

A long-term open-label extension study of CNM-Au8 in relapsing multiple sclerosis has completed phases 2 and 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• CNM-Au8 (CNM-Au8)

Snippet

Sponsor: Clene Nanomedicine | Conditions: Relapsing Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED